CompletedPhase 2

Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients

United States21 participantsStarted 2016-04

Plain-language summary

This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs. The investigators will be using Pembrolizumab as the treating agent.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕-Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.

What they're measuring

Overall Response Rate Via Endoscopic Lesional Burden Score and/or RECIST

Timeframe: Up to 2 years

Number of Participants With Adverse Events Through CTCAE

Timeframe: Up to 3 years after enrollment of the last the patient

Trial details

NCT IDNCT02632344

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-02

Results submitted2023-04-18

View on ClinicalTrials.gov More Recurrent Respiratory Papillomatosis trials